WA
ABMD

Winfield Associates’s Abiomed Inc ABMD Stock Holding History

Winfield Associates’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5
Closed -$1K – 713
2017
Q4 		$1K Buy
+5
New +$934 ﹤0.01% 810
2017
Q1 		– Sell
-10
Closed -$1K – 807
2016
Q4 		$1K Buy
+10
New +$1.16K ﹤0.01% 688

Other funds holding ABMD

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

Winfield Associates's ABMD Position: Q1 2018 in Review

Winfield Associates sold out of Abiomed Inc (ABMD) in Q1 2018, closing a stake of 5 shares — an estimated $1K sold.

Winfield Associates first reported a position in ABMD in Q4 2016 and held it in 2 quarters. The position peaked at $1K in Q4 2017. 405 funds tracked by Wall St. Rank hold ABMD as of Q1 2018.

  • Winfield Associates reported no remaining Abiomed Inc position as of Q1 2018 after selling out during the quarter.
  • Winfield Associates sold 5 Abiomed Inc shares in Q1 2018, an estimated $1K.
  • Winfield Associates first reported a position in Abiomed Inc in Q4 2016 and held it in 2 quarters.
  • Winfield Associates's Abiomed Inc position peaked at $1K in Q4 2017.
  • 405 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2018.

Based on Winfield Associates's 13F filing for Q1 2018, filed 10 May 2018.